If this conclusion is accurate, then it would indicate a possible target for future research on chronic treatment with TRPV1 agonists in the diabetic and obesity conditions, evaluating whether these agonists could attenuate or prevent vascular dysfunction. Here, TRPV1 is linked to Obesity.